PMID- 29394168 OWN - NLM STAT- MEDLINE DCOM- 20190318 LR - 20211204 IS - 1532-0979 (Electronic) IS - 0147-5185 (Linking) VI - 42 IP - 5 DP - 2018 May TI - Low-grade Endometrioid Stromal Sarcoma of the Paratestis: A Novel Report With Molecular Confirmation of JAZF1/SUZ12 Translocation. PG - 695-700 LID - 10.1097/PAS.0000000000001030 [doi] AB - Tumors with Mullerian-like serous or mucinous phenotypes originating in the testis and its adnexa are rare neoplasms that have been increasingly recognized in recent years. Cystadenomas with or without ovarian-type stroma, borderline tumors, and adenocarcinomas are the main documented types. Although a handful cases of putative endometrioid adenocarcinomas have been reported, to our knowledge no case of endometrial stromal-type neoplasm has ever been reported in the literature. A 59-year-old man presented with a 2 cm left intrascrotal mass that was found on sonographic examination to arise from the epididymal tail with prominent vascularization. He was otherwise healthy without significant clinical history, endocrinopathy, or external hormone therapy. His testicular tumor markers (beta-HCG, AFP) were normal. Histologic examination of the resection showed a multinodular tumor closely associated with the epididymis and composed of monotonous rounded to ovoid cells with scanty cytoplasm and prominent spiral-like arterioles and capillaries. Mitotic activity was high. No other tumor component was seen. Immunohistochemistry revealed strong and diffuse expression of vimentin, CD10, estrogen receptor, and progesterone receptor. Molecular examination (performed on paraffin-embedded tumor tissue using a 517 gene fusion next-generation sequencing assay) showed a JAZF1/SUZ12 translocation, which was then confirmed by fluorescence in situ hybridization (FISH). These findings are consistent with a low-grade endometrioid stromal sarcoma originating in the paratestis. This report represents a novel addition to the growing spectrum of Mullerian-analog testicular adnexal neoplasms. FAU - Agaimy, Abbas AU - Agaimy A AD - Institute of Pathology, Friedrich-Alexander University of Erlangen-Nuremberg, University Hospital of Erlangen, Erlangen. FAU - Moskalev, Evgeny A AU - Moskalev EA AD - Institute of Pathology, Friedrich-Alexander University of Erlangen-Nuremberg, University Hospital of Erlangen, Erlangen. FAU - Weisser, Wera AU - Weisser W AD - Institute for Hematopathology. FAU - Bach, Thorsten AU - Bach T AD - Department of Urology, Asklepios Clinic Harburg, Hamburg, Germany. FAU - Haller, Florian AU - Haller F AD - Institute of Pathology, Friedrich-Alexander University of Erlangen-Nuremberg, University Hospital of Erlangen, Erlangen. FAU - Hartmann, Arndt AU - Hartmann A AD - Institute of Pathology, Friedrich-Alexander University of Erlangen-Nuremberg, University Hospital of Erlangen, Erlangen. LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Am J Surg Pathol JT - The American journal of surgical pathology JID - 7707904 RN - 0 (Biomarkers, Tumor) RN - 0 (Co-Repressor Proteins) RN - 0 (DNA-Binding Proteins) RN - 0 (JAZF1 protein, human) RN - 0 (Neoplasm Proteins) RN - 0 (SUZ12 protein, human) RN - 0 (Transcription Factors) RN - EC 2.1.1.43 (Polycomb Repressive Complex 2) SB - IM MH - Biomarkers, Tumor/analysis/*genetics MH - Co-Repressor Proteins MH - DNA-Binding Proteins MH - Female MH - Genetic Predisposition to Disease MH - Humans MH - Immunohistochemistry MH - In Situ Hybridization, Fluorescence MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Proteins/*genetics MH - Phenotype MH - Polycomb Repressive Complex 2/*genetics MH - Sarcoma, Endometrial Stromal/chemistry/*genetics/pathology/surgery MH - Testicular Neoplasms/chemistry/*genetics/pathology/surgery MH - Transcription Factors MH - Translocation, Genetic EDAT- 2018/02/03 06:00 MHDA- 2019/03/19 06:00 CRDT- 2018/02/03 06:00 PHST- 2018/02/03 06:00 [pubmed] PHST- 2019/03/19 06:00 [medline] PHST- 2018/02/03 06:00 [entrez] AID - 10.1097/PAS.0000000000001030 [doi] PST - ppublish SO - Am J Surg Pathol. 2018 May;42(5):695-700. doi: 10.1097/PAS.0000000000001030.